Clinical trial
ISIS 3521 in Treating Patients With Advanced, Unresectable, or Metastatic…
NCT00003989 · European Organisation for Research and Treatment of Cancer - EORTC, Other · Completed
Key facts
| NCT number | NCT00003989 |
|---|---|
| Title | ISIS 3521 in Treating Patients With Advanced, Unresectable, or Metastatic Non-small Cell Lung Cancer or Unresectable or Metastatic Melanoma |
| Official title | Phase II Trial With ISIS 3521/CGP 64128A in Patients With Malignant Melanoma and Non Small Cell Lung Cancer |
| Lead sponsor | European Organisation for Research and Treatment of Cancer - EORTC, Other |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Lung Cancer, Melanoma (Skin) |
| Intervention type | Biological |
| Interventions | ISIS 3521 |
| Enrollment | 50 |
| Start date | Jun 1, 1998 |
| First posted | Aug 27, 2004 |
| Last update posted | Jul 11, 2012 |
| Countries | Austria, Belgium, Denmark, France, Germany, Netherlands, Norway, Switzerland, United Kingdom |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: